However, he added that most suppliers were expecting a 5 to15 percent drop in business this year. ENVIRONMENTAL SUSTAINABILITY "I think we need the green shoots to be really green andthere is a real opportunity to make green shoots sustainableshoots in the year ahead" -- Lucy Neville-Rolfe, director ofcorporate and legal affairs at Tesco (TSCO.L) "The consumer is far more enquiring today, far moredemanding and I think as the economy recovers there is going tobe a far more demanding consumer out there" -- Andrew Jennings,managing director of retail at Woolworths South Africa (WHLJ.J). PRICES "We're expecting between 5 and 10 percent price deflation(from suppliers in Asia)" -- William Fung, managing director ofLi & Fung.(Reporting by Mark Potter and Sarah Morris; Editing by RupertWinchester) Stocks Global Markets China. In addition, Inference Metrics provides administrators withthe ability to manage multiple cases from one view. The Inference product applies conceptual search andanalytics to prioritize datasets and find key documents for faster and morecost-effective review.
Inference, a web-based solution, is distinguished byits highly scalable architecture and a user-intuitive, configurable workflow.Inference Data is privately held and headquartered in New York, NY. For moreinformation, visit DataChristina Pandapas, +1-339-927-7788, . Track record in business software, successful partnerships and acquisitionsstrengthens Firm58's leadership team.CHICAGO, May 6 /PRNewswire/ -- Firm58, Inc (), the leader inon-demand post-trade software, today announced that Nick Fera has beenappointed Chief Executive Officer. Fera comes to Firm58 with more than 22years of software industry experience, most recently as Chairman and CEO ofParlano, maker of the enterprise group chat platform MindAlign which wasacquired by Microsoft in October 2007.Fera joins Firm58 at a time when capital market companies are recognizing thegrowing value of using on-demand software as a way to cut cost and time.Firm58 brings efficiency and transparency, and cost savings to middle and backoffice processes by offering automated solutions such as billing andreconciliation, and by eliminating the need for large up front softwarepurchases. At Firm58, Fera will serve on the board of directors and beresponsible for daily operations and company strategy."The opportunity to join Firm58 was compelling," noted Fera. Fera also has extensivespeaking experience having presented more than 100 times on finance issueslike company valuation to the American Management Association and variousuniversities.About Firm58, Inc.Based in Chicago, Firm58 offers on-demand post-trade management softwaresolutions to manage critical operations such as position management, billing,reconciliation, payment, fees and commission calculations, in addition tocustomer, financial and operational analytics.
By automating all post-tradeprocesses regardless of asset class (equities, foreign exchange, fixed income,futures), Firm58 enables organizations to increase revenues whilesimultaneously reducing costs. Firm58 is backed by New World Ventures andNorth Bridge Venture Partners. For more information please visit Firm58 .SOURCEFirm58, Inc.Jessica Mean, +1-312-863-2390, Ext. 231, , for Firm58,Inc..
DUBLIN--(Business Wire)--Research andMarkets( http://) hasannounced the addition of the "Celiac Disease - Licensing Opportunities Exist inUntapped Market" report to their offering. Low disease awareness, poor diagnosis rates, combined with a lack ofpharmaceutical industry involvement, has kept celiac disease from the limelight.However, this is changing as evidenced by Shires recent involvement in thepipeline. Datamonitor believes a drug for celiac disease is up to 5 years awayand this untapped gastrointestinal indication has the potential to become alucrative market. Scope* Review of epidemiology, issues with diagnosis - both current techniques andthose with future potential - and management of celiac disease, are discussed * Commercial assessment of celiac disease, including market access scenarios andpatient number forecast * An overview of unmet needs, the celiac disease pipeline and clinical trialdesign * Stakeholder opinions based on qualitative interviews with six key opinionleaders in the field of celiac diseaseHighlights of this title A drug launch in celiac disease is up to 5 years away. Datamonitor estimatesthat under optimal conditions drug sales could reach $8 billion by 2019 in theseven major markets. Two market access strategies are available to companies,which are dictated by the targeted celiac disease subpopulation and drug pricepoint. The pipeline is small, and not advanced past Phase II, but candidates showvarious approaches to potentially treating celiac disease.
Small, venture-backedbiopharmaceutical companies power R&D, but Shires recent in-licensing of thelead pipeline candidate AT-1001 (Alba Therapeutics) shows the promise of futureBig Pharma involvement. Low disease awareness among primary care physicians is a major factor behind lowdiagnosis rates5% in the US to 25% in the EUin celiac disease. Continued effortsto increase awareness, especially once a drug comes to market, will drive celiacdisease diagnosis rates up to 50%-60% by 2019, which will expand the overallpatient population. PHILADELPHIA--(Business Wire)--RAIT Financial Trust ("RAIT") (NYSE: RAS) today announced results for the firstquarter ended March 31, 2009.